Abstract: INFO10-FR
Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity (AIM-AHEAD): West Hub
Session Information
- Informational Posters - II
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- No subcategory defined
Author
- Nicholas, Susanne B., University of California Los Angeles, Los Angeles, California, United States
Group or Team Name
- AIM-AHEAD West Hub
Description
AIM-AHEAD West Hub
The purpose of AIM-AHEAD West Hub is to promote community engagement
around AI/ML awareness in underserved settings, and knowledge among community health stakeholders. We achieve this by partnering with community-based organizations and safety net health systems in the western areas of AIM-AHEAD. The Western Hub will also support pilot projects with PI’s affiliated with academic and community organizations in the AIM-AHEAD Western region.
Pilot Project Exemplar: Center for Kidney Disease Research, Education and Hope (CURE-CKD)
This collaborative was established to assess the incidence, prevalence, and care of chronic kidney disease (CKD) in two healthcare systems. An infrastructure was created to facilitate and leverage the longstanding research and quality improvement expertise within both the Providence and UCLA systems. We efficiently conduct studies with “Big Data,” derived from electronic health records, to jointly advance awareness, detection, action, and research for CKD. This approach serves dual purposes of informing about the clinical care delivered to patients with, or at-risk for, CKD and producing new knowledge to address unmet needs for this major public health problem.
Providence and UCLA have developed the analytic-ready dataset, governance, legal structure, and technology necessary for intersystem collaborative research. State-of-the-art data analytics are used to rigorously model exposures, risks, and outcomes relevant to CKD. Ultimately, system-level interventions will be tested to enhance quality of care and improve clinical outcomes, while judiciously managing utilization and costs, for some of our most vulnerable patients. As a result, people with, or at-risk for, kidney diseases will have longer and better lives.
Funding
- National Institutes of Health (NIH)